Caris Life Sciences, Inc.(CAI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,290 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CAI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Caris Life Sciences, Inc. (CAI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CAI at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,290 of 2,879 stocks — the bottom half of the AI-ranked universe. CAI scores in the top quartile across institutional flow (83.4). Areas of concern include revenue growth (29.5) and profitability (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Caris Life Sciences, Inc. reports quarterly revenue of $216.2M, net income of $-510.0K, an operating margin of 2.4%. Top institutional holders of CAI by reported 13-F value include FMR, J. H. Whitney Equity Partners VI,, Sixth Street Partners Management Company, L.P., based on the most recent SEC filings. CAI trades on the Nasdaq exchange and files with the SEC under CIK 2019410. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Caris Life Sciences, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$216.2M
Net Income
Q1 2026
$-510.0K
Free Cash Flow
Q1 2026
$22.5M
Operating Margin
Q1 2026
2.4%
ROIC
Q1 2026
0.5%
D/E Ratio
Q1 2026
0.64
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+97.0% YoYNet Income
+75.8% YoYOperating Income
+117.5% YoYEPS (Diluted)
+69.8% YoYTotal Assets
+227.5% YoYTotal Debt
-12.5% YoYOp. Cash Flow
+133.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $812.0M +97.0% | $412.3M +34.7% | $306.1M | — |
| Net Income | $-68.1M +75.8% | $-281.9M +17.4% | $-341.4M | — |
| Operating Income | $45.1M +117.5% | $-257.1M +19.5% | $-319.6M | — |
| EPS (Diluted) | $-3.22 +69.8% | $-10.66 +19.5% | $-13.24 | — |
| Total Assets | $1.13B +227.5% | $343.7M | — | — |
| Total Debt | $379.0M -12.5% | $433.2M | — | — |
| Operating Cash Flow | $83.2M +133.9% | $-245.2M +11.2% | $-276.1M | — |
Get alerted when CAI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Caris Life Sciences, Inc. including:
Top Institutional Holders of CAI
FMR LLC
$550.4M30,785,585 shJ. H. Whitney Equity Partners VI, LLC
$326.4M18,256,615 shSixth Street Partners Management Company, L.P.
$257.2M14,385,399 shCOATUE MANAGEMENT LLC
$175.6M9,819,992 shBRAIDWELL LP
$143.2M8,009,447 shPointState Capital LP
$131.6M7,360,446 shBlackRock, Inc.
$86.8M4,857,112 shVANGUARD PORTFOLIO MANAGEMENT LLC
$67.2M3,758,462 shNeuberger Berman Group LLC
$64.2M3,590,586 shVANGUARD CAPITAL MANAGEMENT LLC
$59.5M3,329,021 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $550.4M | 30,785,585 |
| J. H. Whitney Equity Partners VI, LLC | $326.4M | 18,256,615 |
| Sixth Street Partners Management Company, L.P. | $257.2M | 14,385,399 |
| COATUE MANAGEMENT LLC | $175.6M | 9,819,992 |
| BRAIDWELL LP | $143.2M | 8,009,447 |
| PointState Capital LP | $131.6M | 7,360,446 |
| BlackRock, Inc. | $86.8M | 4,857,112 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $67.2M | 3,758,462 |
| Neuberger Berman Group LLC | $64.2M | 3,590,586 |
| VANGUARD CAPITAL MANAGEMENT LLC | $59.5M | 3,329,021 |
More Healthcare Companies
View all Healthcare →Put CAI on your watchlist
Track score changes the day Caris Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CAI a good stock to buy?
13F Pro's AI-powered analysis of Caris Life Sciences, Inc. (CAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CAI are available on the CAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CAI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Caris Life Sciences, Inc.'s investment landscape.